[ effect of different doses of maprotiline on the treatment of Iranian patients suffering from moderate MDD]

Treatment effect of maprotiline at different doses [50-150 mg/d] as a tetracyclic antidepressant, with major effects on NEP and less anticholinergic side effects compared to some other tricyclic medications, has been compared with other medications. Given ethical and cultural differences as well as pharmacokinetic characteristics between Iranian populations, the current study was carried out to determine the effect of different doses of maprotiline in treatment of moderate MDD, its therapeutic ratio and related side effects in each dose, and also to define the effective dose of maprotiline. This quasi-experimental study was performed on the patients with moderate MDD who referred to psychiatry clinics. Thirty cases were selected from the patient with age between 25- 50 years, with 20

double blind placebo controlled study comparing the CNS and antimuscarinic side effect of amitriptyline and maprotiline

A double blind placebo controlled cross over study randomized in a latin square design was conducted at Pharmacology Department of Rawalpindi Medical College on twelve healthy human volunteers of either sex, with ages between 20-25 years and a body weight between 50-60 kg to compare the C.N.S. and antimuscarinic side effects of tricyclic [Amitryptyline] and tetracyclic [Maprotiline] antidepressants Results revealed that amitriptyline causes more sedation than maprotiline. The antimuscarinic effects like dryness of mouth, decrease in salivary volume and impairment of visual accommodation are also more prominent with amitriptyline compared with maprotiline